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recommended high volumes of fluid administration, and
have recommended fluid restriction for diseases where
fluid overload could develop.
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Active vitamin D agents
and refractory
hyperparathyroidism in
dialysis patients
To the Editor: In the March 2005 issue of Kidney Inter-
national, Nakanishi et al [1] presented a very interesting
study showing that only serum levels of fibroblast growth
factor-23 (FGF-23) were significantly related to the prog-
nosis of parathyroid function in dialysis patients. The fac-
tors they included in their stepwise regression analysis
were serum FGF-23, calcium, phosphate, intact PTH, in-
tact osteocalcin, bone-specific alkaline phosphatase lev-
els, age, and dialysis vintage [1]. They did not include
treatment with active vitamin D agents, even though
the pretreatment serum FGF-23 levels were significantly
higher in those patients (47 out of 103) who were receiv-
ing vitamin D. A very recent paper by Foley et al [2]
showed that parathyroidectomy was associated, among
other factors, also with the previous use of IV vitamin D
(hazards ratio 2.44, P < 0.0001). Furthermore, we showed
that nodular hyperplasia of parathyroid glands was signif-
icantly associated with IV calcitriol pulse therapy (CPT)
in hemodialysis patients [3]. The simplest explanation for
the paradoxic association between this histologic pattern
and IV CPT could be that CPT is often attempted as
a “final” nonsurgical strategy when parathyroidectomy
is being considered [2]. On the contrary, we hypothe-
sized that, paradoxically, long-term IV CPT might be
among the factors determining nodular hyperplasia: in
fact, a disturbed and/or decreased action of long-term
IV CPT at the level of the parathyroid cell might cause
progression into the cell cycle and a disinhibition of c-
myc expression, leading to a more aggressive nodular
type proliferation of parathyroid glands [4]. Therefore,
we kindly ask Nakanishi et al to reanalyze their data, in-
cluding vitamin D treatment in their stepwise regression
analysis.
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Reply from the Authors
Thank you for your interest in our recent paper [1].
We agree with you that the cumulative dosage of active
vitamin D therapy may correlate with the severity of sec-
ondary hyperparathyroidism. However, we believe that
the more intensive vitamin D therapy should be the con-
sequence, but not the cause, of the nodular transforma-
tion of parathyroid cells, since such cells displayed less
sensitivity to vitamin D [2].
We have reported that the use of active vitamin D
agents may be related to the increased serum FGF-23 lev-
els in dialysis patients [1, 3, 4]. Therefore, we needed to
avoid applying FGF-23 and active vitamin D therapy to-
gether as independent variables when performing a step-
wise regression analysis. Although it may be possible to
perform a stepwise analysis applying active vitamin D
therapy instead of FGF-23, it must be “active vitamin D
therapy throughout the observation period,” but not “ac-
tive vitamin D therapy at the beginning of the observation
period.”
Furthermore, the physicians in charge changed treat-
ment strategy depending upon the plasma intact PTH
levels in our study. Accordingly, “active vitamin D ther-
apy throughout the observation period” was obviously a
